HealthMap

Gene Therapy and Micro-Dystrophin Delivery

Overview

• Gene therapy for conditions like Duchenne Muscular Dystrophy (DMD) focuses on delivering a shortened, functional version of the dystrophin gene, known as micro-dystrophin.
• Because the full-size dystrophin gene is too large to fit into standard viral vectors (such as AAV), a compressed genetic code must be used.

Biological and Metabolic Effects

• Restoration of Structural Integrity: The delivered micro-dystrophin helps stabilize the muscle cell membrane (sarcolemma), reducing contraction-induced damage and preventing excessive leakage of intracellular enzymes like creatine kinase.
• Biochemical Balance: By improving structural support, it indirectly helps normalize intracellular calcium homeostasis, which is typically disrupted in dystrophic muscle tissue.
• Immune System Interaction:
• The body may recognize the newly expressed micro-dystrophin or the viral capsid as foreign.
• This can trigger cellular and humoral immune responses, potentially limiting long-term efficacy or requiring immunosuppressive protocols.

Nutritional and Cellular Considerations

• High Metabolic Demand: Gene therapy alters cellular dynamics, increasing the need for optimal cellular nutrition to support protein synthesis and muscle tissue repair.
• Antioxidant Support: Reduced oxidative stress is critical, as inflammation often accompanies viral vector administration.
• Enzymatic and Cofactor Status: Adequate availability of specific minerals and vitamins is essential for supporting cellular regeneration pathways following vector delivery.